+No debtClose to casflow neutral/positivefairly Stable and high...

+
No debt
Close to casflow neutral/positive
fairly Stable and high top 20 %
Billionaire tops up 2m @ 20c
Increasing sales Q on Q

-
Lacks liquidity
Needs better PR from company (take example horse nebulizer, no announcement), CEO role stil effectively vacant.
A couple new hirings to management and shuffle of board (Delk)
Lack of breakdown and insight into medivet business


Overall, 100% better on where they were 12-18mths back. I can see the concern for some, hence the SP halving, however the turnover has been lackluster, it doesn't look like the big holders running for the exits... I personally sit on a bundle.of these and have no intention of selling. Happy for this to be my LT biotech holding, but each to there own, dyor etc.

Cheers